Related Experiment Video
Updated: Aug 1, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Matrix Metalloproteinase-Responsive PEGylated Lipid Nanoparticles for Controlled Drug Delivery in the Treatment of
Liming He1, Donghao Fan1, Wenlang Liang1
1Key Laboratory of Advanced Technologies of Materials, Ministry of Education and School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
Abstract:
Rheumatoid arthritis (RA) is an autoimmune disorder. It causes inflammation, swelling, and pain in the joints of the human body. Overexpressed matrix metalloproteinases (MMPs) at the inflammatory sites of RA are a target in the construction of inflammation-responsive drug delivery vehicles for enhancing the therapeutic effect of anti-inflammatory drugs in the treatment of RA. In this paper, we report MMP-responsive PEGylated lipid nanoparticles through the co-assembly of triglycerol monostearate (TGMS) and 1,2-distearoyl-sn-glycero-3-phospho-ethanolamine-poly(ethyleneglycol) (DSPE-PEG2000) in which the ester bond of TGMS is cleavable by MMPs and the PEG chain provides a stealth layer. The lipid nanoparticles show high biocompatibility, extended blood circulation, and preferential distribution in the inflammatory joints of RA. The loaded dexamethasone (Dex) can be rapidly released from the lipid nanoparticles in response to MMPs. After being intravenously administered to arthritic rats, Dex-loaded MMP-responsive PEGylated lipid nanoparticles significantly reduce the degree of joint swelling and inhibit the production of TNF-α and IL-1β in joint tissues. These results demonstrate that MMP-responsive PEGylated lipid nanoparticles are a smart drug vehicle for the treatment of RA with improved therapeutic efficacy.
Insights
New PEGylated lipid nanoparticles are designed to respond to matrix metalloproteinases (MMPs) in rheumatoid arthritis (RA) joints. These smart drug delivery vehicles enhance anti-inflammatory drug efficacy for improved RA treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Drug Delivery Systems
Background:
- Rheumatoid arthritis (RA) is an autoimmune disease causing joint inflammation and pain.
- Overexpressed matrix metalloproteinases (MMPs) in RA joints are key targets for drug delivery.
- Current treatments can be limited by drug distribution and efficacy.
Purpose of the Study:
- To develop MMP-responsive PEGylated lipid nanoparticles for RA treatment.
- To investigate the drug release, biocompatibility, and biodistribution of these nanoparticles.
- To evaluate the therapeutic efficacy of dexamethasone-loaded nanoparticles in an arthritic rat model.
Main Methods:
- Co-assembly of triglycerol monostearate (TGMS) and DSPE-PEG2000 to form MMP-responsive nanoparticles.
- Loading dexamethasone (Dex) into the nanoparticles.
- In vitro and in vivo evaluation in an arthritic rat model, assessing joint swelling and inflammatory markers (TNF-α, IL-1β).
Main Results:
- The nanoparticles exhibited high biocompatibility and prolonged blood circulation.
- Preferential accumulation of nanoparticles in inflamed RA joints was observed.
- Rapid release of Dex in response to MMPs and significant reduction in joint swelling and inflammation markers in vivo.
Conclusions:
- MMP-responsive PEGylated lipid nanoparticles represent a promising smart drug delivery system for RA.
- These nanoparticles enhance the therapeutic efficacy of anti-inflammatory drugs like dexamethasone.
- The developed system offers improved treatment outcomes for rheumatoid arthritis.
